Basic Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Exp Med. Jun 20, 2025; 15(2): 102761
Published online Jun 20, 2025. doi: 10.5493/wjem.v15.i2.102761
Cytoplasmic and nuclear programmed death ligand 1 expression in peritumoral stromal cells in breast cancer: Prognostic and predictive value
Evgeniya Yu Zubareva, Marina A Senchukova, Natalia V Saidler
Evgeniya Yu Zubareva, Marina A Senchukova, Department of Oncology, Orenburg State Medical University, Orenburg 460021, Orenburgskaya Oblast, Russia
Natalia V Saidler, Department of Pathology, Orenburg Regional Cancer Clinic, Orenburg 460021, Orenburgskaya Oblast, Russia
Author contributions: Zubareva EY designed and performed the research, and wrote the paper; Senchukova MA acquired and analyzed the data and contributed substantially to the conception and design of the study; Saidler NV participated in the discussion of related data, and revised and approved the final version; All authors wrote and approved the final manuscript.
Supported by Russian Science Foundation, No. 23-25-00183.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of Orenburg State Medical University (Russia, Orenburg; protocol No. 311 dated January 13, 2023).
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Data sharing statement: Data from patients included in the study in Statistica10 table or Excel table formats can be provided upon request to the corresponding author at masenchukova@yandex.com.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Marina A Senchukova, MD, PhD, Professor, Department of Oncology, Orenburg State Medical University, 6 Sovetskaya Street, Orenburg 460000, Orenburgskaya Oblast, Russia. masenchukova@yandex.com
Received: October 28, 2024
Revised: January 21, 2025
Accepted: February 21, 2025
Published online: June 20, 2025
Processing time: 170 Days and 4.8 Hours
Core Tip

Core Tip: Programmed death ligand 1 expression was studied in breast cancer (BC) stromal cells using a new antibody against programmed cell death protein 1 ligand 1 (PDCD1 LG1). This study revealed that moderate and pronounced PDCD1 LG1 expression in polymorphic cell infiltrates and the presence of PDCD1 LG1 expression in the fibroblastic stroma are associated with unfavorable BC prognosis. Additionally, PDCD1 LG1+ lymphocyte score ≥ 3 in the absence of lymphovascular invasion (LVI) is associated with a reduced risk of BC regional metastasis; by contrast, in the presence of LVI, it is associated with an increased risk of regional BC metastasis.